Antiepileptic drugs and tourette syndrome

International Review of Neurobiology

Volumn 112, Issue , 2013, Pages 373-389

  Cavanna, Andrea E ^a,b,c   Nani, Andrea ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Levetiracetam; Tics; Topiramate; Tourette syndrome; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; APOMORPHINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CANNABINOID; CITALOPRAM; CLONIDINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; ETIRACETAM; GUANFACINE; HALOPERIDOL; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NICOTINE; NORADRENALIN; OLANZAPINE; PERGOLIDE; PIMOZIDE; PLACEBO; RISPERIDONE; SULPIRIDE; TETRABENAZINE; TIAPRIDE; TOPIRAMATE;

ACADEMIC ACHIEVEMENT; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE DURATION; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FRONTAL CORTEX; GILLES DE LA TOURETTE SYNDROME; HUMAN; IRRITABILITY; MEDICAL RESEARCH; MENTAL DISEASE; MOOD DISORDER; MOTOR DYSFUNCTION; NEUROIMAGING; OBSESSIVE COMPULSIVE DISORDER; PATHOPHYSIOLOGY; PERSONALITY DISORDER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; SIDE EFFECT; SOMNOLENCE; STRIATE CORTEX; TIC; TREATMENT DURATION; WEIGHT REDUCTION;

LEVETIRACETAM; TICS; TOPIRAMATE; TOURETTE SYNDROME; TREATMENT;

ANTICONVULSANTS; HUMANS; NEUROTRANSMITTER AGENTS; TOURETTE SYNDROME;

EID: 84888422835     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-411546-0.00012-3     Document Type: Chapter

References (79)

1. Abelson J.F., Kwan K.Y., O'Roak B.J., Baek D.Y., Stillman A.A., Morgan T.M., et al. Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science 2005, 310:317-320.
2. Abuzzahab F.S., Brown V.L. Control of Tourette syndrome with topiramate. American Journal of Psychiatry 2001, 158:968.
3. Alexander G.E., DeLong M.R., Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuroscience 1986, 9:357-381.
4. American Psychiatric Association Diagnostic and statistical manual for mental disorders 2000, American Psychiatric Association, Washington, DC, Text Revision (DSM-IV-TR). 4th ed.
5. Anavekar S.N., Jarrott B., Toscano M., Louis W.J. Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects. European Journal of Clinical Pharmacology 1982, 23:1-5.
6. Awaad Y., Michon A.M., Minarik S. Use of levetiraceram to treat tics in children and adolescents with Tourette syndrome. Movement Disorders 2005, 20:714-718.
7. Awaad Y., Minarik S. Long-term follow-up use of levetiracetam to treat tics in children. Annals of Neurology 2005, 58:S112.
8. Barkley R.A., DuPaul G.J., McMurray M.B. Attention deficit disorder with and without hyperactivity: Clinical response to three dose levels of methylphenidate. Pediatrics 1991, 87:519-531.
9. Bronfeld M., Bar-Gad I. Tic disorder: What happens to the basal ganglia?. The Neuroscientist 2013, 19:101-108.
10. Cavanna A.E., Critchley H.D., Orth M., Stern J.S., Young M.-B., Robertson M.M. Dissecting the Gilles de la Tourette spectrum: A factor analytic study on 639 patients. Journal of Neurology, Neurosurgery, and Psychiatry 2011, 82:1320-1323.
11. Cavanna A.E., Martino D., Orth M., Giovannoni G., Stern J., Robertson M.M., et al. Neuropsychiatric-developmental model for the expression of tics, pervasive developmental disorder, and schizophreniform symptomatology associated with PANDAS. World Journal of Biological Psychiatry 2009, 10:1037-1038.
12. Cavanna A.E., Rickards H. The psychopathological spectrum of Gilles de la Tourette syndrome. Neuroscience and Biobehavioral Reviews 2013, 37:1008-1015.
13. Cavanna A.E., Robertson M.M., Critchley H.D. Schizotypal personality traits in Gilles de la Tourette syndrome. Acta Neurologica Scandinavica 2007, 116:385-391.
14. Cavanna A.E., Servo S., Monaco F., Robertson M.M. The behavioral spectrum of Gilles de la Tourette syndrome. Journal of Neuropsychiatry and Clinical Neurosciences 2009, 21:13-23.
15. Cohen D.J., Young J.G., Nathanson J.A., Shaywitz B.A. Clonidine in Tourette's syndrome. Lancet 1979, 2:551-553.
16. Como P.G., LaMarsh J., O'Brien K.A. Obsessive-compulsive disorder in Tourette's syndrome. Advances in Neurology 2005, 96:249-261.
17. DeLong M.R., Georgopoulos A.P., Crutcher M.D., Mitchell S.J., Richardson R.T., Alexander G.E. Functional organization of the basal ganglia: Contributions of single-cell recording studies. Ciba Foundation Symposium 1984, 107:64-78.
18. Draganski B., Martino D., Cavanna A.E., Hutton C., Orth M., Robertson M.M., et al. Multispectral brain morphometry in Tourette syndrome persisting into adulthood. Brain 2010, 133:3661-3675.
19. Drtilkova I., Balastikova B., Lemanova H., Zak J. Therapeutic effects of clonidine and clonazepam in children with tic syndrome. Homeostasis in Health and Disease 1994, 35:296.
20. Eapen V., Pauls D.L., Robertson M.M. Evidence for autosomal dominant transmission in Tourette's syndrome: A United Kingdom cohort study. British Journal of Psychiatry 1993, 162:593-596.
21. Eddy C.M., Rickards H.E., Cavanna A.E. Treatments strategies for tics in Tourette syndrome. Therapeutic Advances in Neurological Disorders 2011, 4:25-45.
22. Eddy C.M., Rickards H.E., Cavanna A.E. The cognitive impact of antiepileptic drugs. Therapeutic Advances in Neurological Disorders 2011, 4:385-407.
23. Eddy C.M., Rickards H.E., Cavanna A.E. Behavioral adverse effects of antiepileptic drugs in epilepsy. Journal of Clinical Psychopharmacology 2012, 32:362-375.
24. Fernández-Jaén A., Fernández-Mayoralas D.M., Muñoz-Jareño N., Calleja-Pérez B. An open-label, prospective study of levetiracetam in children and adolescents with Tourette syndrome. European Journal of Paediatric Neurology 2009, 13:541-545.
25. Frank M., Piedad J., Rickards H., Cavanna A.E. The role of impulse control disorders in Tourette syndrome: An exploratory study. Journal of the Neurological Sciences 2011, 310:276-278.
26. Freeman R.D., Fast D.K., Burd L., Kerbeshian J., Robertson M.M., Sandor P. An international perspective on Tourette's syndrome: Selected findings from 3,500 individuals in 22 countries. Developmental Medicine and Child Neurology 2000, 42:436-447.
27. Frey K.A., Albin R.L. Neuroimaging of Tourette's syndrome. Journal of Child Neurology 2006, 21:672-677.
28. Goetz C.G. Clonidine and clonazepam in Tourette syndrome. Advances in Neurology 1992, 58:245-251.
29. Goetz C.G., Tanner C.M., Wilson R.S., Carroll V.S., Como P.G., Shannon K.M. Clonidine and Gilles de la Tourette's syndrome: Double-blind study using objective rating methods. Annals of Neurology 1987, 21:307-310.
30. Gomer B., Wagner K., Frings L., Saar J., Carius A., Härle M., et al. The influence of antiepileptic drugs on cognition: A comparison of levetiracetam with topiramate. Epilepsy & Behavior 2007, 10:486-494.
31. Gonce M., Barbeau A. Seven cases of Gilles de la Tourette's syndrome: Partial relief with clonazepam. A pilot study. Canadian Journal of Neurological Sciences 1977, 3:279-283.
32. Haber S.N., Kim K.S., Mailly P., Calzavara R. Reward-related cortical inputs define a large striatal region in primates that interfaces with associative cortical connections, providing a substrate for incentive-based learning. Journal of Neuroscience 2006, 26:8368-8376.
33. Haber S.N., Lynd E., Klein C., Groenewegen H.J. Topographic organization of the ventral striatal efferent projections in the rhesus monkey: An anterograde tracing study. Journal of Comparative Neurology 1990, 293:282-298.
34. Hedderick E.F., Morris C.M., Singer H.S. Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatric Neurology 2009, 40:420-425.
35. Helmstaedter C., Fritz N.E., Kockelmann E., Kosanetzsky N., Elger C.E. Positive and negative psychotropic effects of levetiracetam. Epilepsy & Behavior 2008, 13:535-541.
36. Huang C.-W., Pai M.-C., Tsai J.-J. Comparative cognitive effects of levetiracetam and topiramate in intractable epilepsy. Psychiatry and Clinical Neurosciences 2008, 62:548-553.
37. Jankovic J. Tourette's syndrome. New England Journal of Medicine 2001, 345:1184-1192.
38. Jankovic J., Jimenez-Shahed J., Brown L.W. A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. Journal of Neurology, Neurosurgery, and Psychiatry 2010, 81:70-73.
39. Keen-Kim D., Freimer N.B. Genetics and epidemiology of Tourette's syndrome. Journal of Child Neurology 2006, 21:665-671.
40. Khalifa N., von Knorring A.L. Tourette's syndrome and other tic disorders in a total population of children: Clinical assessment and background. Acta Paediatrica 2005, 94:1608-1614.
41. Kovacs M. The children's depression inventory (CDI). Psychopharmacology Bulletin 1985, 21:995-998.
42. Leckman J.F. Tourette's syndrome. Lancet 2002, 360:1577-1586.
43. Leckman J.F., Hardin M.T., Riddle M.A., Stevenson J., Ort S.I., Cohen D.J. Clonidine treatment of Gilles de la Tourette's syndrome. Archives of General Psychiatry 1991, 48:324-328.
44. Leckman J.F., Riddle M.A., Hardin M.T., Ort S.I., Swartz K.L., Stevenson J., et al. The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity. Journal of the American Academy of Child and Adolescent Psychiatry 1989, 28:566-573.
45. Lee H.W., Jung D.K., Suh C.K., Kwon S.H., Park S.P. Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: A 1-year follow-up. Epilepsy & Behavior 2006, 8:736-741.
46. Levisohn P.M., Mintz M., Hunter S.J., Yang H.C., Jones J. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: A randomized, double-blind, placebo-controlled, noninferiority trial. Epilepsia 2009, 50:2377-2389.
47. López-Góngora M., Martinez-Domeño A., García C., Escartín A. Effect of levetiracetam on cognitive functions and quality of life: A one-year follow-up study. Epileptic Disorders 2008, 10:297-305.
48. Lyseng-Williamson K.A., Yang L.P. Topiramate: A review of its use in the treatment of epilepsy. Drugs 2007, 67:2231-2256.
49. March J.S., Parker J.D., Sullivan K., Stallings P., Conners C.K. The multidimensional anxiety scale for children (MASC): Factor structure, reliability, and validity. Journal of the American Academy of Child and Adolescent Psychiatry 1997, 36:554-565.
50. Mula M., Cavanna A.E., Monaco F. Psychopharmacology of topiramate: From epilepsy to bipolar disorder. Neuropsychiatric Disease and Treatment 2006, 2:475-488.
51. Ondo W.G., Jankovic J., Connor G.S., Pahwa R., Elble R., Stacy M.A., et al. Topiramate in essential tremor: A double-blind, placebo-controlled trial. Neurology 2006, 66:672-677.
52. Opp J., Tuxhorn I., May T., Kluger G., Wiemer-Kruel A., Kurlemann G., et al. Levetiracetam in children with refractory epilepsy: A multicenter open label study in Germany. Seizure 2005, 14:476-484.
53. Patsalos P.N. The pharmacokinetic characteristics of levetiracetam. Methods and Findings in Experimental and Clinical Pharmacology 2003, 25:123-129.
54. Pauls D.L., Towbin K.E., Leckman J.F., Zahner G.E., Cohen D.J. Gilles de la Tourette syndrome and obsessive-compulsive disorder: Evidence supporting a genetic relationship. Archives of General Psychiatry 1986, 43:1180-1182.
55. Pelham W.E., Carlson C., Sams S.E., Vallano G., Dixon M.J., Hoza B. Separate and combined effects of methylphenidate and behavior modifications on boys with attention deficit-hyperactivity disorder in the classroom. Journal of Consulting and Clinical Psychology 1993, 61:506-515.
56. Piazzini A., Chifari R., Canevini M.P., Turner K., Fontana S.P., Canger R. Levetiracetam: An improvement of attention and of oral fluency in patients with partial epilepsy. Epilepsy Research 2006, 68:181-188.
57. Piedad J., Rickards H., Besag F., Cavanna A.E. Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: A summary of prevalence, underlying mechanisms and data limitations. CNS Drugs 2012, 26:319-335.
58. Poulain P., Margineanu D.G. Levetiraceram opposes the action of GABAA antagonists in hypothalamic neurons. Neuropharmacology 2002, 42:346-352.
59. Robertson M.M. Tourette syndrome, associated conditions and the complexities of treatment. Brain 2000, 123:425-462.
60. Robertson M.M. Tourette's syndrome. Child psychiatry 2005, Vol. IV:92-97. The Medicine Publishing Company Group, Psychiatry. D. Skuse (Ed.).
61. Robertson M.M. Attention deficit hyperactivity disorder, tics and Tourette's syndrome: The relationship and treatment implications. European Child and Adolescent Psychiatry 2006, 15:1-11.
62. Robertson M.M. Gilles de la Tourette syndrome: The complexities of phenotype and treatment. British Journal of Hospital Medicine 2011, 72:100-107.
63. Robertson M.M., Cavanna A.E. Tourette syndrome: The facts 2008, Oxford University Press, Oxford.
64. Robertson M.M., Gourdie A. Familial Tourette's syndrome in a large British pedigree: Associated psychopathology, severity, and potential for linkage analysis. British Journal of Psychiatry 1990, 156:515-521.
65. Roessner V., Plessen K.J., Rothenberger A., Ludolph A.G., Rizzo R., Skov L., et al. ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorder. Part II: Pharmacological treatment. European Child and Adolescent Psychiatry 2011, 20:173-196.
66. Scahill L., Erenberg G., Berlin C.M., Budman C., Coffey B.J., Jankovic J., et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. Journal of the American Society for Experimental NeuroTherapeutics 2006, 3:192-206.
67. Scahill L., Riddle M.A., McSwiggin-Hardin M., Ort S.I., King R.A., Goodman W.K., et al. Children's yale-brown obsessive compulsive scale: Reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry 1997, 36:844-852.
68. Shafran R. Obsessive compulsive disorder in children and adolescent. Child Psychology & Psychiatry Review 2001, 6:50-58.
69. Simpson H.A., Jung L., Murphy T.K. Update on attention-deficit/hyperactivity disorder and tic disorder: A review of the current literature. Current Psychiatry Reports 2011, 13:351-356.
70. Singer H.S., Brown J., Quaskey S., Rosenberg L.A., Mellits E.D., Denckla M.B. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: A double blind placebo-controlled study with clonidine and desipramine. Pediatrics 1995, 95:74-81.
71. Singer H.S., Minzer K. Neurobiology of Tourette syndrome: Concepts of neuroanatomic localization and neurochemical abnormalities. Brain and Development 2003, 25:S70-S84.
72. Smith-Hicks C., Bridges D.D., Paynter N.P., Singer H.S. A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Movement Disorders 2007, 22:1764-1770.
73. Steingard R.J., Goldberg M., Lee D., De Maso D.R. Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 1994, 33:394-399.
74. Swain J.E., Leckman J.F. Tourette's syndrome in children. Current Treatment Options in Neurology 2003, 5:299-308.
75. Thomas R., Cavanna A.E. The pharmacology of Tourette syndrome. Journal of Neural Transmission 2013, 120:689-694.
76. Tourette Syndrome Classification Study Group Definitions and classification of tic disorders. Archives of Neurology 1993, 50:1013-1016.
77. Troung D.D., Bressman S., Shale H., Fahn S. Clonazepam, haloperidol, and clonidine in tic disorders. Southern Medical Journal 1988, 81:1103-1105.
78. Wright A., Rickards H., Cavanna A.E. Impulse control disorders in Gilles de la Tourette syndrome. Journal of Neuropsychiatry and Clinical Neurosciences 2012, 24:16-27.
79. Zhu Y., Leung K.M., Liu P.Z., Zhou M., Su L.Y. Comorbid behavioral problems in Tourette's syndrome are persistently correlated with the severity of tic symptoms. Australian and New Zealand Journal of Psychiatry 2006, 40:67-73.